Top Markets
#1 ONFA ONFA +217.91%
#2 Resolv wstUSR Resolv wstUSR +198.08%
#3 Noon Noon +41.33%
#4 Doge Strategy Doge Strategy +38.28%
#5 DeAgentAI DeAgentAI +36.64%
#6 NKN NKN +34.87%
#7 StakeStone StakeStone +29.44%
#8 BLOCKv BLOCKv +25.50%
#9 KONET KONET +24.76%
#10 OpenVPP OpenVPP +21.34%
Coin of the day
ONFA ONFA
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Classement en actions #19706
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Prix de l'action
$0.5275
Capitalisation boursière
$1.25M
Changement (1 jour)
-3.56%
Changement (1 an)
-83.77%
Pays
US
Échange Ensysce Biosciences, Inc. (ENSC)

Catégorie

Healthcare
Bénéfices pour Ensysce Biosciences, Inc. (ENSC)
Bénéfices en Sep 2025 TTM : $-10.97M
Selon les derniers rapports financiers de Ensysce Biosciences, Inc., les bénéfices actuels de l'entreprise sont de $-10.97M. En 2023, l'entreprise a réalisé un bénéfice de $-10.63M, une augmentation par rapport à celui de 2022 qui était de $-24.21M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Ensysce Biosciences, Inc. de 2017 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2026 (TTM) $-10.97M 37.39%
2024 $-7.99M -24.84%
2023 $-10.63M -56.10%
2022 $-24.21M -16.94%
2021 $-29.15M 18,017.11%
2020 $-160.88K -98.41%
2019 $-10.10M -477.51%
2018 $2.68M -9,810.43%
2017 $-27.56K 0.00%
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B -186,530.54%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B -42,414.51%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B -47,768.53%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -19,581.29%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -14,811.33%
AU